R
Ri Yao Yang
Researcher at University of Texas MD Anderson Cancer Center
Publications - 36
Citations - 3932
Ri Yao Yang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Galectin & Immunotherapy. The author has an hindex of 20, co-authored 33 publications receiving 3358 citations. Previous affiliations of Ri Yao Yang include Scripps Research Institute & La Jolla Institute for Allergy and Immunology.
Papers
More filters
Journal ArticleDOI
Role of the Carboxyl-Terminal Lectin Domain in Self-Association of Galectin-3†
TL;DR: Evidence is obtained suggesting that galectin-3 can self-associate through intermolecular interactions involving both the amino- and the carboxyl-terminal domains and the relative contribution of each depends on whether the lectin is bound to its saccharide ligands.
Book ChapterDOI
Galectins in apoptosis.
TL;DR: This review describes involvement of galectin-1, -2, -3, -7, -8, -9, and -12 in apoptosis.
Journal ArticleDOI
Galectin-3 Regulates Intracellular Trafficking of EGFR through Alix and Promotes Keratinocyte Migration
Wei Liu,Daniel K. Hsu,Huan Yuan Chen,Ri Yao Yang,Kermit L. Carraway,Roslyn Rivkah Isseroff,Roslyn Rivkah Isseroff,Fu-Tong Liu +7 more
TL;DR: The results suggest that galectin-3 is potentially a critical regulator of a number of important cellular responses through its intracellular control of trafficking of cell surface receptors.
Journal Article
Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing.
Linlin Sun,Ri Yao Yang,Chia Wei Li,Mei-Kuang Chen,Mei-Kuang Chen,Bin Shao,Bin Shao,Jung-Mao Hsu,Li Chuan Chan,Li Chuan Chan,Yi Yang,Jennifer L. Hsu,Jennifer L. Hsu,Yun-Ju Lai,Mien Chie Hung,Mien Chie Hung,Mien Chie Hung +16 more
TL;DR: Findings indicate that in addition to potentiating DNA damage, ATR inhibitor concurrently downregulates PD-L1 levels and enhances anti-tumor immune responses, revealing a potential crosstalk between DNA damage response signaling and immune checkpoints.
Journal ArticleDOI
Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity
Linlin Sun,Linlin Sun,Chia Wei Li,Chia Wei Li,Ezra M. Chung,Ri Yao Yang,Kim Yong Soo,Andrew H. Park,Yun-Ju Lai,Yi Yang,Yu Han Wang,Yu Han Wang,Jielin Liu,Yufan Qiu,Kay-Hooi Khoo,Jun Yao,Jennifer L. Hsu,Jong Ho Cha,Li Chuan Chan,Jung-Mao Hsu,Jung-Mao Hsu,Heng Huan Lee,Stephen S. Yoo,Mien Chie Hung +23 more
TL;DR: PD-1 is extensively N-glycosylated in T cells and the intensities of its specific glycoforms are altered upon TCR activation, which provides novel insights into the functional significance of PD-1 glycosylation and offers a rationale for targeting glyCosylated PD- 1 as a potential strategy for immunotherapy.